Evidence map›Paper›PMID 33268514›Full record

ArticleJournal of virology2021

The Fiber Knob Protein of Human Adenovirus Type 49 Mediates Highly Efficient and Promiscuous Infection of Cancer Cell Lines Using a Novel Cell Entry Mechanism.

Alexander T Baker, James A Davies, Emily A Bates, Elise Moses, Rosie M Mundy, Gareth Marlow, David K Cole, Carly M Bliss, Pierre J Rizkallah, Alan L Parker

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Adenovirus Structure: What Is New?International journal of molecular sciences · 2021
    Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Alexander T BakerDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom.ORCID 0000-0001-8232-0531
James A DaviesDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Emily A BatesDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Elise MosesDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Rosie M MundyDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Gareth MarlowDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom.
David K ColeDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Carly M BlissDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Pierre J RizkallahDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Alan L ParkerDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom ParkerAL@Cardiff.ac.uk.ORCID 0000-0002-9302-1761
Cardiff University · GB

Funding

Cancer Research UK 29104Cancer Research UK C52915/A29104Cancer Research UK C7838/A25173Wellcome TrustWellcome Trust 517732Wellcome Trust AC1170IF04
6 · The paper itself

Abstract

The human adenovirus (HAdV) phylogenetic tree is diverse, divided across seven species and comprising over 100 individual types. Species D HAdV are rarely isolated with low rates of preexisting immunity, making them appealing for therapeutic applications. Several species D vectors have been developed as vaccines against infectious diseases, where they induce robust immunity in preclinical models and early phase clinical trials. However, many aspects of the basic virology of species D HAdV, including their basic receptor usage and means of cell entry, remain understudied. Here, we investigated HAdV-D49, which previously has been studied for vaccine and vascular gene transfer applications. We generated a pseudotyped HAdV-C5 presenting the HAdV-D49 fiber knob protein (HAdV-C5/D49K). This pseudotyped vector was efficient at infecting cells devoid of all known HAdV receptors, indicating HAdV-D49 uses an unidentified cellular receptor. Conversely, a pseudotyped vector presenting the fiber knob protein of the closely related HAdV-D30 (HAdV-C5/D30K), differing in four amino acids from HAdV-D49, failed to demonstrate the same tropism. These four amino acid changes resulted in a change in isoelectric point of the knob protein, with HAdV-D49K possessing a basic apical region compared to a more acidic region in HAdV-D30K. Structurally and biologically we demonstrate that HAdV-D49 knob protein is unable to engage CD46, while potential interaction with coxsackievirus and adenovirus receptor (CAR) is extremely limited by extension of the DG loop. HAdV-C5/49K efficiently transduced cancer cell lines of pancreatic, breast, lung, esophageal, and ovarian origin, indicating it may have potential for oncolytic virotherapy applications, especially for difficult to transduce tumor types.

Indexed as

Genetic VectorsVirus InternalizationAdenoviruses, HumanCapsid ProteinsCell Line, TumorHumansNeoplasmsOncolytic VirotherapyReceptors, Virusadenovirus receptorCapsid Proteinshexon capsid protein, AdenovirusReceptors, Virusadenovirusesanticancer therapyoncolytic virusessurface receptor

Identifiers

PMID33268514
PMCPMC7851562
OpenAlexW3106782526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.